Expanded Access to ABT-414

Official Title: 
Expanded Access to ABT-414
Brief Summary: 
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
EA Type
Individual Patients
Intermediate-size Population
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis

Drug: ABT-414
ABT-414 will be administered by intravenous infusion

Eligibility Criteria: 

Inclusion Criteria:

- Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.

- Health Care Provider (HCP) must have prior clinical trial experience with ABT-414.

- The participant must not be eligible for an ABT-414 clinical trial.

- Pediatric participants may be evaluated on a case by case basis

Eligibility Gender: 
Eligibility Age: 
Minimum: 18 Years


AbbVie Inc.
Study Director

EA Number: 
Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme
MeSH Terms: 
Glioblastoma, Immunoconjugates
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about